Researchers Find Zoledronic Acid May Reduce Bone Loss in HIV Patients
One of the many effects HIV (the human immunodeficiency virus) has on the human body is the loss of bone density. This bone loss causes many HIV patients to suffer frequent fractures without much trauma.
Researchers from several medical schools recently published the results of Phase II clinical trials for a new treatment method. The report, which the researchers gave at the 2016 Conference on Retroviruses and Oppportunistic Infections, detailed the effects of zoledronic acid on HIV-infected patients.
The trials included 63 HIV-positive individuals with no history of osteoperosis and normal levels of Vitamin D and calcium. These participants were treated with zoledronic acid and antiretroviral therapy (ART) or a placebo and ART. Those who received the zoledronic acid saw a 73 percent reduction in bone loss at 12 weeks of treatment, and 65 percent at 24 weeks.
Patients on the zoledronic acid also saw an eight percent rise in lumbar spine bone marrow density at 12 weeks, a rate which increased to 11 percent at later benchmarks. Researchers will need to complete further testing to certify the zoledronic acid treatment as a safe and useful treatment for use in conjunction with ART.
HIV and AIDS Can Result in Bone Loss and Disability as They Progress
The ongoing decline of health associated with HIV and AIDS (acquired immunodeficiency syndrome) can cause levels of impairment that make working impossible. If you or a loved one can no longer work due to AIDS or HIV, Disability Help Group can help you seek Social Security disability benefits on their behalf. Contact us online or call us at 1-(800)-800-3332 to schedule a consultation with our disability advocates.